 "Department of Pharma consults stakeholders on pricing mechanism for stents")
The Department of Pharmaceuticals has involved hospitals and eminent clinicians, both from the government and private sectors in the important discussion on price control of coronary stents.
In this discussion on the subject of coronary stents’ inclusion in NLEM (National List of Essential Medicine), according to FICCI press release, several reputed clinicians have emphasised on the fact that all drug eluting stents (DES) cannot be considered the same. There is sufficient clinical evidence that generational improvements in DES through incremental innovation has resulted in improved patient outcomes in the form of reduced rate of thrombosis and restenosis reduction for instance, in addition to ease of deliverability thus improving overall safety and efficacy. The suggestion that all DES is similar puts Indian patients and medical care in significant quality disadvantage.
The reputed clinicians’ experts present in the meeting have recommended to the Government to consider a DES classification norm through a matrix that involves such key performance parameters as type of drug & alloy; strut thickness; polymer profile; deliverability & trackability; global regulatory approvals; and published safety & efficacy outcome data.
There was consensus amongst clinicians, government and industry that an appropriate ‘scoring matrix’, with critical patient safety and efficacy parameters, should be designed to determine DES classification. Industry has requested the government to follow up through a multi stakeholder determination workshop, involving reputed clinicians, to design the matrix before government activates the pricing mechanism for stents in NLEM.
FICCI, which has always maintained that all DES cannot be considered same and submitted extensive evidence of that to the NLEM expert committee in the past, has welcomed the Department of Pharmaceutical’s latest move towards a science, safety and efficacy based DES price determination process.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%